Loading...
•
Jun 30, 2025
Roivant Sciences Q1 2025 Earnings Report
Roivant Sciences reported financial results for Q1 2025 and provided a business update.
Key Takeaways
Roivant Sciences reported a net income of $57.5 million for the quarter ended June 30, 2024, compared to a net loss of $327.8 million for the same period in 2023. VTAMA net product revenue was $18.4 million. The company's consolidated cash, cash equivalents, and restricted cash stood at $5.7 billion as of June 30, 2024.
Immunovant completed enrollment in batoclimab pivotal myasthenia gravis (MG) trial.
Brepocitinib development in non-infectious uveitis (NIU) is progressing to Phase 3.
VTAMA net product revenue was $18.4M for the first quarter ended June 30, 2024.
Roivant reported its consolidated cash, cash equivalents and restricted cash of $5.7B at June 30, 2024.
Forward Guidance
Roivant anticipates several milestones in the coming quarters, including PDUFA action for VTAMA in atopic dermatitis in Q4 2024, topline data from the Phase 2 trial of namilumab for sarcoidosis in Q4 2024, and initiation of a Phase 3 program for brepocitinib in NIU in the second half of 2024.
Positive Outlook
- Dermavant expects PDUFA action for VTAMA in atopic dermatitis in the fourth quarter of calendar year 2024.
- Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the fourth quarter of calendar year 2024.
- Priovant plans to report topline data from the ongoing Phase 3 trial of brepocitinib in DM in the second half of calendar year 2025 and to initiate a Phase 3 program for brepocitinib in NIU in the second half of calendar year 2024.
- Immunovant plans to have initiated 4-5 potentially registrational programs by March 31, 2025, and plans to have initiated studies in a total of 10 indications by March 31, 2026, for IMVT-1402.
- Immunovant expects to have at least 3 IND applications active by the end of calendar year 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...